Article Details
Retrieved on: 2025-02-11 21:12:14
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Toray's asset TRK-950 is a monoclonal antibody targeting Caprin-1 that is in Phase 2 development for Gastric cancer, providing validation for this ...
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here